Gilead Sciences Inc. (GILD) Shares Sold by Acrospire Investment Management LLC
Acrospire Investment Management LLC lowered its position in shares of Gilead Sciences Inc. (NASDAQ:GILD) by 38.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,900 shares of the biopharmaceutical company’s stock after selling 1,200 shares during the period. Acrospire Investment Management LLC’s holdings in Gilead Sciences were worth $158,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. First Financial Corp IN raised its position in shares of Gilead Sciences by 3.1% in the first quarter. First Financial Corp IN now owns 7,422 shares of the biopharmaceutical company’s stock worth $682,000 after buying an additional 225 shares during the last quarter. Van Cleef Asset Management Inc raised its position in shares of Gilead Sciences by 0.8% in the first quarter. Van Cleef Asset Management Inc now owns 61,797 shares of the biopharmaceutical company’s stock worth $5,677,000 after buying an additional 476 shares during the last quarter. BLB&B Advisors LLC purchased a new position in shares of Gilead Sciences during the first quarter worth $268,000. Nicolet Bankshares Inc. raised its position in shares of Gilead Sciences by 2.5% in the first quarter. Nicolet Bankshares Inc. now owns 4,760 shares of the biopharmaceutical company’s stock worth $437,000 after buying an additional 117 shares during the last quarter. Finally, BTR Capital Management Inc. raised its position in shares of Gilead Sciences by 5.3% in the first quarter. BTR Capital Management Inc. now owns 82,802 shares of the biopharmaceutical company’s stock worth $7,606,000 after buying an additional 4,165 shares during the last quarter. Hedge funds and other institutional investors own 77.94% of the company’s stock.
Gilead Sciences Inc. (NASDAQ:GILD) traded up 1.62% on Friday, hitting $79.12. 11,031,540 shares of the company traded hands. The stock’s 50-day moving average is $79.40 and its 200 day moving average is $85.53. Gilead Sciences Inc. has a 12 month low of $76.67 and a 12 month high of $111.11. The stock has a market cap of $104.41 billion, a PE ratio of 6.94 and a beta of 1.06.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Monday, July 25th. The biopharmaceutical company reported $3.08 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $3.02 by $0.06. Gilead Sciences had a net margin of 50.50% and a return on equity of 106.75%. The company had revenue of $7.78 billion for the quarter, compared to the consensus estimate of $7.80 billion. During the same period last year, the firm posted $3.15 EPS. Gilead Sciences’s revenue for the quarter was down 5.7% on a year-over-year basis. Equities research analysts expect that Gilead Sciences Inc. will post $11.76 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Thursday, September 29th. Shareholders of record on Friday, September 16th were given a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a yield of 2.38%. The ex-dividend date was Wednesday, September 14th. Gilead Sciences’s payout ratio is currently 16.56%.
GILD has been the subject of several recent research reports. Robert W. Baird reiterated an “outperform” rating and issued a $135.00 price target on shares of Gilead Sciences in a research report on Monday, June 6th. Morgan Stanley reiterated a “hold” rating on shares of Gilead Sciences in a research report on Monday, June 6th. Maxim Group reiterated a “hold” rating on shares of Gilead Sciences in a research report on Wednesday, June 8th. Leerink Swann reiterated a “buy” rating and issued a $120.00 price target (down previously from $123.00) on shares of Gilead Sciences in a research report on Thursday, June 9th. Finally, Zacks Investment Research lowered Gilead Sciences from a “hold” rating to a “sell” rating in a research report on Monday, June 13th. Ten research analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have issued a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $105.00.
In other Gilead Sciences news, CEO John F. Milligan sold 112,000 shares of the firm’s stock in a transaction on Tuesday, July 5th. The shares were sold at an average price of $84.33, for a total transaction of $9,444,960.00. Following the transaction, the chief executive officer now directly owns 1,170,963 shares of the company’s stock, valued at approximately $98,747,309.79. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider John C. Martin sold 100,000 shares of the firm’s stock in a transaction on Monday, August 1st. The stock was sold at an average price of $80.50, for a total transaction of $8,050,000.00. Following the transaction, the insider now directly owns 4,119,727 shares in the company, valued at $331,638,023.50. The disclosure for this sale can be found here. Company insiders own 1.40% of the company’s stock.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.